<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03888144</url>
  </required_header>
  <id_info>
    <org_study_id>17-872</org_study_id>
    <nct_id>NCT03888144</nct_id>
  </id_info>
  <brief_title>Study of Ketorolac Versus Opioid for Pain After Endoscopy</brief_title>
  <acronym>SKOPE</acronym>
  <official_title>Study of Ketorolac Versus Opioid for Pain After Endoscopy (SKOPE): A Double-blinded Randomized Control Trial Comparing Outpatient Analgesic Efficacy of NSAIDs and Opioids in Patients Undergoing Ureteroscopy for Kidney Stones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double blind randomized controlled trial designed to compare pain control and safety with
      ketorolac and oxycodone in the post-operative setting for patients undergoing ureteroscopy
      for treatment of urinary stones. Patients are followed for five days after their surgery as
      they record their pain scores, medication utilization, and stent related symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Pain Score</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>Averaged pain score over five days post-operatively (measured 0 to 10 mm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ureteric Stent Symptom Questionnaire</measure>
    <time_frame>Post-operative days 1 and 5</time_frame>
    <description>A validated assessment tool for stent-related symptoms and their impact on patient quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adverse Effects</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>Patient-reported medication related side effects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain Medication utilization</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>Blinded study drug daily usage or alternative over the counter pain medication utilization. Additionally the proportion of patients in each group who utilized the provided &quot;rescue&quot; oxycodone pills.</description>
  </other_outcome>
  <other_outcome>
    <measure>Healthcare contact regarding refractory pain</measure>
    <time_frame>Up to Two months post-op</time_frame>
    <description>Occurrence of contacting healthcare professionals through a phone call, office visit, physician message or emergency room visit regarding refractory pain.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Kidney Calculi</condition>
  <condition>Ureteral Calculi</condition>
  <arm_group>
    <arm_group_label>Oxycodone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to 20 pills of 5 mg oxycodone by mouth every 6 hours as needed for pain after ureteroscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to 20 pills of 10 mg ketorolac by mouth every 6 hours as needed for pain after ureteroscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>5 mg of oxycodone taken by mouth every 6 hours for 5 days</description>
    <arm_group_label>Oxycodone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>10 mg of ketorolac taken by mouth every 6 hours for 5 days</description>
    <arm_group_label>Ketorolac group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with kidney or ureteral stones confirmed on imaging (CT of the abdomen
             pelvis) and who elect for definitive treatment via unilateral ureteroscopy at one of
             two hospital sites within a tertiary care institution

          -  Patients who post-operatively receive a unilateral ureteral stent

          -  Capable of giving informed consent

          -  Capable and willing to fulfill requirements of the study

        Exclusion Criteria:

          -  Active or history of peptic ulcer disease, gastrointestinal bleeding or perforation

          -  History of coronary artery bypass graft surgery

          -  History of a bleeding disorder

          -  GFR less than 60 mL/min/1.73m2 (MDRD equation)

          -  Chronic use of opioid or other pain medication including NSAIDs (greater than 12
             weeks)

          -  Known allergy to either ketorolac or oxycodone

          -  Known or suspected pregnancy

          -  Solitary kidney

          -  Patients taking anticoagulant medication or antiplatelet medication (e.g. warfarin,
             clopidogrel, pradaxa, rivaroxaban, apixaban etc).

          -  Inability to give informed consent or unable to meet requirements of the study for any
             reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriharan Sivalingam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naveen Kachroo, MD</last_name>
    <phone>216-973-5227</phone>
    <email>kachron@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Faris, BA</last_name>
    <phone>650-200-7359</phone>
    <email>farisa2@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajat Jain, MD</last_name>
      <phone>513-255-6699</phone>
      <email>rkjain1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna Faris, BA</last_name>
      <phone>650-200-7359</phone>
      <email>farisa2@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sriharan Sivalingam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manoj Monga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Noble, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Stern, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luay Alshara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajat Jain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naveen Kachroo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Smita De, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03888144/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

